2020-12-21,"Company News for Dec 21, 2020"
2020-12-18,"Ultragenyx (RARE), Mereo Ink Deal for Bone Disease Candidate"
2020-12-18,"The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data"
2020-12-17,Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta
2020-12-17,Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta
2020-12-15,"Mereo BioPharma Provides Update on AIM Delisting and Continued Listing of its ADSs on Nasdaq, and Provides Update on agreements with Silicon Valley Bank and Kreos Capital"
2020-12-07,Is MREO A Good Stock To Buy Now?
2020-11-23,"Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development"
2020-11-16,"Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020"
2020-11-10,Mereo BioPharma to Present at the Stifel 2020 Virtual Healthcare Conference
2020-10-20,"Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs"
2020-10-19,Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)
2020-09-29,"Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update"
2020-09-24,Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta
2020-09-16,"Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2020 and Host Conference Call on September 29, 2020"
2020-09-04,What Type Of Shareholders Own The Most Number of Mereo BioPharma Group plc (LON:MPH) Shares?
2020-08-25,Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease
2020-08-17,Billionaire Steven Cohen Pulls the Trigger on These 3 Penny Stocks
2020-06-30,"Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development"
2020-06-16,"Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019"
2020-06-04,Mereo BioPharma Announces Completion of $70 Million Private Placement
2020-03-27,Business Update and Directorate Change
2020-02-28,Mereo BioPharma Announces Positive Feedback from Type B End-of-Phase 2 Meeting with the FDA and Outlines Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta
2020-02-19,"The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA"
2020-02-19,Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
2020-02-12,Mereo BioPharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab
2020-02-11,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology"
2020-02-10,"Mereo BioPharma Enters into a $5 Million Convertible Equity Financing with Novartis and Announces a Securities Purchase Agreement with Aspire Capital Fund, LLC for up to $28 Million"
2020-01-14,Mereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory Progress
2020-01-13,Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
2019-11-11,Mereo BioPharmas Setrusumab Demonstrates Dose-Dependent Bone Building and Trend in Fracture Reduction in Phase 2b ASTEROID Study in Adults with Osteogenesis Imperfecta
2019-10-09,Mereo BioPharma Sees Hammer Chart Pattern: Time to Buy?
2019-10-07,Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer
2019-09-17,"Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2019 and Provides Corporate Update"
2019-09-10,"Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 17, 2019"
2019-09-04,Mereo BioPharma Announces Setrusumab 6-Month Phase 2b Data in Osteogenesis Imperfecta Selected for Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting
2019-07-16,Mereo BioPharma Appoints Richard Francis as Head of Pharmaceutical Development
2019-07-15,Mereo BioPharma Announces Successful Type B Meeting with U.S. FDA and Outlines Accelerated Approval Pathway for Navicixizumab in Advanced Ovarian Cancer
2019-06-14,"The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA"
2019-06-13,Mereo BioPharma Group plc (Mereo or the Company or the Group) Update on Etigilimab (TIGIT) Partnership
2019-05-30,"The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug"
2019-05-30,"Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the Anti-Sclerostin Antibody, BPS-804 (setrusumab)"
2019-05-03,Mereo BioPharma Group plc (Mereo or the Company or the Group) Intention to Purchase Shares by Trustee of Employee Benefit Trust
2019-04-29,"Mereo BioPharma Group Plc (""Mereo"" or the ""Company"" or the ""Group"") Preliminary Results for the Year Ended December 31, 2018 -- Strong Operational Progress"
2019-04-26,"Mereo Biopharma to Announce Preliminary Results for the Full Year 2018 and Host Conference Call on April 29, 2019"
2019-04-24,"Mereo BioPharma Group plc (""Mereo"" or the ""Company"" or the ""Group"") Admission to trading on AIM of New Shares and initiation of trading on Nasdaq of American Depositary Shares"
